Personalized oncology aims to match each patient to a specific therapy based on the molecular characteristics of their tumor.

Currently, tumor DNA is sequenced, and genomics reports are given to physicians to help select targeted therapies for patients.

While this genome-centric approach to precision oncology has extended the lives of subsets of patients, many patients do not respond to the selected therapy and many whose tumors initially respond have a high chance of recurrence with resistant disease.

New approaches are required to capture complex clinical phenotypes and better match patients to efficacious therapies.

Viewers will gain insights into:

• An understanding of state-of-the-art proteomic analyses
• Application of proteogenomic approaches to identifying novel biomarkers
• How to develop multiplex, targeted proteomic assays to support preclinical and clinical studies

Dr. Amanda Paulovich, MD, PhD, Professor and Aven Foundation Endowed Chair, Director, CLIA Targeted Proteomic Laboratory, Clinical Research Division, Fred Hutchinson Cancer Center

As an oncologist, Dr. Amanda Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized medicine.” Through these experiences, she became passionate about developing technologies and strategies for the translation of NextGen diagnostics and therapeutics to enable precision medicine.

Over the past 19 years, Dr. Paulovich’s interdisciplinary laboratory has focused on proteogenomic approaches to understanding cancer biology and laying the groundwork for the clinical translation of NextGen diagnostics incorporating targeted, multiple reaction monitoring (MRM) mass spectrometry.

Dr. Paulovich completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in oncology at Dana-Farber Cancer Institute. She completed her PhD training in genetics with Dr. Lee Hartwell at the University of Washington and postdoctoral training in genomics at the Massachusetts Institute of Technology with Dr. Eric Lander.

Personalized oncology aims to match each patient to a specific therapy based on the molecular characteristics of their tumor.

Currently, tumor DNA is sequenced, and genomics reports are given to physicians to help select targeted therapies for patients.

While this genome-centric approach to precision oncology has extended the lives of subsets of patients, many patients do not respond to the selected therapy and many whose tumors initially respond have a high chance of recurrence with resistant disease.

New approaches are required to capture complex clinical phenotypes and better match patients to efficacious therapies.

Viewers will gain insights into:

• An understanding of state-of-the-art proteomic analyses
• Application of proteogenomic approaches to identifying novel biomarkers
• How to develop multiplex, targeted proteomic assays to support preclinical and clinical studies

Dr. Amanda Paulovich, MD, PhD, Professor and Aven Foundation Endowed Chair, Director, CLIA Targeted Proteomic Laboratory, Clinical Research Division, Fred Hutchinson Cancer Center

As an oncologist, Dr. Amanda Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized medicine.” Through these experiences, she became passionate about developing technologies and strategies for the translation of NextGen diagnostics and therapeutics to enable precision medicine.

Over the past 19 years, Dr. Paulovich’s interdisciplinary laboratory has focused on proteogenomic approaches to understanding cancer biology and laying the groundwork for the clinical translation of NextGen diagnostics incorporating targeted, multiple reaction monitoring (MRM) mass spectrometry.

Dr. Paulovich completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in oncology at Dana-Farber Cancer Institute. She completed her PhD training in genetics with Dr. Lee Hartwell at the University of Washington and postdoctoral training in genomics at the Massachusetts Institute of Technology with Dr. Eric Lander.